Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To
compare the effectiveness of two different amphotericin B doses in the treatment of
biopsy-proven Candida esophagitis. To determine if low-dose amphotericin B is less toxic than
standard dose therapy during a limited treatment period. To evaluate pharmacokinetic and
pharmacodynamic parameters of the two different dosing regimens.